Hair-fixing and hair-loss-preventing composition, application thereof and hair-fixing and hair-loss-preventing product

Abstract

The invention discloses a hair-fixing and hair-loss-preventing composition, application thereof and a hair-fixing and hair-loss-preventing product. The hair fixing and hair loss preventing composition comprises 17-type collagen, a plant extract and adenosine substances, wherein the plant extract comprises a cacumen biotae extract. On the basis of inhibiting 5alpha-reductase and resisting oxidation, the composition disclosed by the invention also has the effects of fixing hair and preventing hair loss by virtue of ways of relieving inflammatory response, activating hair papilla cells, maintaining health of the hair papilla cells, reducing hair follicle senescence cells and the like.

Description

Technical Field

[0001] The present invention relates to the field of cosmetics, and particularly to a hair-fixing and anti-hair loss composition and its application, as well as a hair-fixing and anti-hair loss product. Background Art

[0002] The problem of hair loss is multi-dimensional, and its impact is not limited to the physical appearance level, but more widely involves multiple aspects such as mental health, social activities, economic status, and medical health. From a psychological perspective, hair loss can significantly reduce an individual's self-esteem and self-image perception, thereby inducing negative psychological states such as anxiety and depression, having an adverse impact on social activities, and in severe cases, may even lead to social isolation. At the same time, gender identity and personal attractiveness may also be affected by hair loss. In the field of sociology, the negative impact of hair loss on career development cannot be ignored, especially in those professional fields with strict appearance requirements, where the impact is more significant. In addition, hair loss may also interfere with the evaluation of self-confidence and attractiveness in interpersonal relationships, reducing the overall quality of life. Economically, the financial burden brought by hair loss treatment cannot be ignored, including the high costs of hair transplantation and special hair care products.

[0003] Hair loss is a complex physiological phenomenon affected by multiple factors. There are many reasons for hair loss. External environments such as ultraviolet rays, chemical substances, and heat treatment can all damage the hair and exacerbate hair loss. Research shows that nutritional status is also crucial for hair health. Lack of nutrients such as protein, iron, zinc, and vitamins will directly affect hair growth and quality. At the same time, certain systemic diseases, such as thyroid diseases and autoimmune diseases, are also closely related to hair loss. Drug use is also a major cause of hair loss. Many drugs, such as chemotherapy drugs and antidepressants, may cause hair loss. Scalp health problems cannot be underestimated either. Microbial imbalance, fungal infection, and inflammatory diseases can all lead to hair loss. Psychological factors such as stress and anxiety indirectly affect hair growth by influencing hormone levels and the immune system. Physical damage, bad hair care habits, and physiological processes such as pregnancy and childbirth may also cause hair loss. Finally, as people age, the hair growth cycle changes, which is also an important cause of hair loss.

[0004] Genetic factors are also key among the factors affecting hair loss. Especially in androgenetic alopecia, genetic susceptibility plays a decisive role. Changes in hormone levels cannot be ignored either. For example, an increase in androgens will cause hair follicle atrophy, thereby leading to hair loss. Hair follicle stem cells play a key role in the hair growth cycle. The hair growth cycle includes the anagen, catagen, and telogen phases. Among them, hair follicle stem cells are activated during the anagen phase to promote new hair growth. The decline or disorder of hair follicle stem cell function can cause hair loss because it cannot maintain the anagen phase of the hair follicle, resulting in sparse and falling hair. Especially in androgenetic alopecia, androgens may interfere with hair follicle stem cells, causing hair follicle atrophy and hair thinning.

[0005] At present, there are also a very large number of anti-hair loss compositions and formulations on the market. Chinese Patent Application CN118845516A discloses an anti-hair loss composition, which is composed of adenosine, coffee extract, L-carnitine tartrate, copper tripeptide-1, Platycladus orientalis extract and niacinamide. This composition has significant synergistic effects in improving the antioxidant capacity of cells and inhibiting 5α-reductase. However, this composition has no obvious effect on inhibiting the senescence or disorder of hair follicle stem cells and maintaining the growth phase of hair follicles. Summary of the Invention

[0006] To solve the above problems, the present invention provides an anti-hair loss and hair-strengthening composition and its application, as well as an anti-hair loss and hair-strengthening product. On the basis of inhibiting 5α-reductase and antioxidation, the composition of the present invention also exerts the effects of hair strengthening and anti-hair loss through reducing inflammatory response, activating dermal papilla cells, maintaining the health of dermal papilla cells and reducing senescent cells in hair follicles.

[0007] To achieve the above technical objectives, the present invention provides the following technical solutions.

[0008] In a first aspect, the present invention provides an anti-hair loss and hair-strengthening composition, which comprises type XVII collagen, plant extract and adenosine substances, and the plant extract includes Platycladus orientalis extract.

[0009] In the present invention, the type XVII collagen can be obtained by conventional chemical synthesis methods or genetic engineering methods in the art.

[0010] In some embodiments, the molecular weight of the type XVII collagen is 20-200 kDa, such as 23.8 kDa, 97 kDa, 120 kDa or 180 kDa.

[0011] In the present invention, the Platycladus orientalis extract can be extracted from the branches or branches and leaves of the plant Platycladus orientalis (L.) Franco of the family Cupressaceae. The extraction method can be conventional in the art.

[0012] In the present invention, the adenosine substances can be selected from one or more of disodium adenosine triphosphate, cyclic adenosine monophosphate, adenosine phosphate, adenosine triphosphate and adenosine, such as adenosine.

[0013] In the present invention, the adenosine can be formed by connecting N-9 of adenine with C-1 of D-ribose through a β-glycosidic bond, and its chemical formula is C 10 H 13 N 5 O 4 , with a molecular weight of 267.24 and a CAS No. of 58-61-7.

[0014] In some embodiments, the mass ratio of type XVII collagen, the Platycladus orientalis extract, and the adenosine substance is (0.0001 - 0.1) : (0.1 - 5) : (0.001 - 0.5), for example, 1:100:1.

[0015] In some embodiments, the hair strengthening and anti - hair loss composition includes type XVII collagen, Platycladus orientalis extract, and adenosine.

[0016] In some embodiments, the hair strengthening and anti - hair loss composition consists of type XVII collagen, Platycladus orientalis extract, and adenosine.

[0017] In the above - mentioned embodiments, preferably, the mass ratio of type XVII collagen, Platycladus orientalis extract, and adenosine is (0.0001 - 0.1) : (0.1 - 5) : (0.001 - 0.5), for example, 1:100:1.

[0018] In some embodiments, the hair strengthening and anti - hair loss composition further includes carnitine substances, and the carnitine substances are preferably selected from one or more of carnitine, carnitine hydrochloride, acetyl - carnitine hydrochloride, carnitine tartrate, and palmitoyl carnitine.

[0019] In the present invention, the carnitine tartrate, also known as L - carnitine tartrate, can be obtained by reacting L - carnitine with tartaric acid, and its chemical formula is C 18 H 36 N 2 O 12 , with a molecular weight of 472.48 and a CAS No. of 36687 - 82 - 8.

[0020] In some embodiments, the hair strengthening and anti - hair loss composition includes type XVII collagen, Platycladus orientalis extract, adenosine, and carnitine tartrate.

[0021] In some embodiments, the hair strengthening and anti - hair loss composition consists of type XVII collagen, Platycladus orientalis extract, adenosine, and carnitine tartrate.

[0022] In the above - mentioned embodiments, preferably, the mass ratio of type XVII collagen, Platycladus orientalis extract, adenosine, and carnitine tartrate is (0.0001 - 0.1) : (0.1 - 5) : (0.001 - 0.5) : (0.003 - 0.5), for example, 1:100:1:3.

[0023] In some embodiments, in the hair strengthening and anti - hair loss composition, the plant extract further includes plant extracts other than Platycladus orientalis extract, such as one or more of Magnolia officinalis extract, Polygonum multiflorum extract, Zingiber officinale extract, Salvia miltiorrhiza extract, and Coffea arabica extract.

[0024] In the present invention, the Magnolia officinalis extract can be obtained by extracting from the dried root bark, stem bark or branch bark of Magnolia officinalis, a plant of the genus Magnolia in the Magnoliaceae family. The extraction method can be conventional in the art.

[0025] In the present invention, the Polygonum multiflorum extract can be obtained by extracting from the dried tuberous roots of Polygonum multiflorum, a plant of the Polygonaceae family. The extraction method can be conventional in the art.

[0026] In the present invention, the Salvia miltiorrhiza extract can be obtained by extracting from the dried roots and rhizomes of Salvia miltiorrhiza, a plant of the Lamiaceae family. The extraction method can be conventional in the art.

[0027] In the present invention, the coffee extract can be obtained by extracting from coffee fruits or coffee seeds of plants of the genus Coffea in the Rubiaceae family. The extraction method can be conventional in the art.

[0028] In some embodiments, the hair strengthening and anti - hair loss composition comprises type XVII collagen, Platycladus orientalis extract, adenosine and Magnolia officinalis extract.

[0029] In some embodiments, the hair strengthening and anti - hair loss composition consists of type XVII collagen, Platycladus orientalis extract, adenosine and Magnolia officinalis extract.

[0030] In the above - mentioned embodiments, preferably, the mass ratio of type XVII collagen, Platycladus orientalis extract, adenosine and Magnolia officinalis extract is (0.0001 - 0.1):(0.1 - 5):(0.001 - 0.5):(0.1 - 2), for example, 1:100:1:100.

[0031] In some embodiments, the hair strengthening and anti - hair loss composition comprises type XVII collagen, Platycladus orientalis extract and Polygonum multiflorum extract.

[0032] In some embodiments, the hair strengthening and anti - hair loss composition further comprises a peptide substance, and the peptide substance is preferably selected from one or more of myristoyl pentapeptide - 4, myristoyl pentapeptide - 17, myristoyl tetrapeptide - 12, myristoyl hexapeptide - 16, acetyl tetrapeptide - 3, oligopeptide - 41, oligopeptide - 74, copper acetylated peptide, biotin tripeptide - 1, acetyl octapeptide - 2, tripeptide - 1 copper, oligopeptide - 1 and tripeptide - 34 copper.

[0033] In the present invention, the myristoyl pentapeptide - 4 can be obtained by chemical synthesis or genetic engineering methods, and its chemical formula is C 37 H 71 N 7 O 10, with a molecular weight of 774.00 and a CAS No. of 1392416-25-9.

[0034] In the present invention, the acetyl tetrapeptide-3 can be obtained by chemical synthesis or genetic engineering methods, and its chemical formula is C 22 H 39 N 9 O 5 , with a molecular weight of 509.6 and a CAS No. of 827306-88-7.

[0035] In the present invention, the tripeptide-1 copper, also known as copper peptide, tripeptide, blue copper peptide, and copper polypeptide, can be obtained by chemical synthesis or genetic engineering methods, and its chemical formula is C 14 H 23 CuN 6 O 4 + , with a molecular weight of 402.92.

[0036] In some embodiments, the hair strengthening and anti - hair loss composition comprises type XVII collagen, Platycladus orientalis leaf extract, adenosine, and myristoyl pentapeptide - 4.

[0037] In some embodiments, the hair strengthening and anti - hair loss composition consists of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and myristoyl pentapeptide - 4.

[0038] In the above - mentioned embodiments, preferably, the mass ratio of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and myristoyl pentapeptide - 4 is (0.0001 - 0.1):(0.1 - 5):(0.001 - 0.5):(0.001 - 3), for example, 1:100:1:1.

[0039] In some embodiments, the hair strengthening and anti - hair loss composition comprises type XVII collagen, Platycladus orientalis leaf extract, adenosine, and acetyl tetrapeptide - 3.

[0040] In some embodiments, the hair strengthening and anti - hair loss composition consists of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and acetyl tetrapeptide - 3.

[0041] In the above - mentioned embodiments, preferably, the mass ratio of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and acetyl tetrapeptide - 3 is (0.0001 - 0.1):(0.1 - 5):(0.001 - 0.5):(0.003 - 0.5), for example, 1:100:1:3.

[0042] In a second aspect, the present invention provides a hair strengthening and anti - hair loss product, which comprises the hair strengthening and anti - hair loss composition as described above.

[0043] In some embodiments, the hair-fixing and anti-hair loss product is shampoo, hair conditioner, hair essence, body wash or body lotion.

[0044] In a third aspect, the present invention provides the use of the hair-fixing and anti-hair loss composition as described above in the preparation of a hair-fixing and anti-hair loss product.

[0045] On the basis of conforming to common general knowledge in the art, the above preferred conditions can be combined arbitrarily to obtain various preferred examples of the present invention.

[0046] The reagents and raw materials used in the present invention are all commercially available.

[0047] The positive and progressive effects of the present invention are as follows:

[0048] 1. The present invention uses type XVII collagen, Platycladus orientalis leaf extract and adenosine in combination. On the basis of inhibiting 5α-reductase and antioxidation, it also exerts the effects of hair fixation and anti-hair loss by activating dermal papilla cells, maintaining the health of dermal papilla cells and reducing follicular senescent cells. In addition, the composition of the present invention also has the effect of reducing inflammatory response.

[0049] 2. The preferred composition of the present invention combines other plant extracts, carnitine substances or peptide substances on the basis of type XVII collagen, Platycladus orientalis leaf extract and adenosine, and exerts the effects of anti-hair loss, hair fixation and hair nourishment from multiple perspectives.

[0050] 3. The composition of the present invention is easy to obtain materials, safe, healthy and has stable efficacy, and is suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 It is a schematic diagram of the test results of the 5α-reductase inhibition rate test of different compositions in each example.

[0052] Figure 2 It is a schematic diagram of the test results of the antioxidant capacity test of different compositions in each example.

[0053] Figure 3 It is a schematic diagram of the test results of the ability to promote COL17 expression of different compositions in each example.

[0054] Figure 4 It is a schematic diagram of the test results of the ability to promote TGF-β2 expression of different compositions in each example.

[0055] Figure 5 It is a schematic diagram of the test results of the ability to promote VEGFA expression of different compositions in each example.

[0056] Figure 6 It is a schematic diagram of the test results of the ability to reduce follicular senescent cells of different compositions in each example. Detailed Implementation Modes

[0057] The present invention will be further described below by way of examples, but the present invention is not limited to the scope of the described examples. For the experimental methods without specific conditions indicated in the following examples, they are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0058] Raw materials such as type XVII collagen, adenosine, L-carnitine tartrate, Platycladus orientalis leaf extract, Magnolia officinalis extract, myristoyl pentapeptide-4, acetyl tetrapeptide-3, Polygonum multiflorum extract, Zingiber officinale extract, coffee extract, and Acorus calamus extract are all purchased from raw material suppliers.

[0059] The manufacturer and model information of each raw material component are as follows:

[0060]

[0061] Example 1 Preparation of Hair-Strengthening and Hair-Loss Prevention Composition 1

[0062] Mix type XVII collagen, Platycladus orientalis leaf extract, and adenosine in a mass ratio of 1:100:1 to obtain hair-strengthening and hair-loss prevention composition 1.

[0063] For subsequent tests, dissolve hair-strengthening and hair-loss prevention composition 1 in water to prepare an aqueous solution, and the contents of type XVII collagen, Platycladus orientalis leaf extract, and adenosine in the solution are 0.001%, 0.1%, and 0.001% respectively.

[0064] Example 2 Preparation of Hair-Strengthening and Hair-Loss Prevention Composition 2

[0065] Mix type XVII collagen, Platycladus orientalis leaf extract, adenosine, and L-carnitine tartrate in a mass ratio of 1:100:1:3 to obtain hair-strengthening and hair-loss prevention composition 2.

[0066] For subsequent tests, dissolve hair-strengthening and hair-loss prevention composition 2 in water to prepare an aqueous solution, and the contents of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and L-carnitine tartrate in the solution are 0.001%, 0.1%, 0.001%, and 0.003% respectively.

[0067] Example 3 Preparation of Hair-Strengthening and Hair-Loss Prevention Composition 3

[0068] Mix type XVII collagen, Platycladus orientalis leaf extract, adenosine, and Magnolia officinalis extract in a mass ratio of 1:100:1:100 to obtain hair-strengthening and hair-loss prevention composition 3.

[0069] For subsequent tests, dissolve hair-strengthening and hair-loss prevention composition 3 in water to prepare an aqueous solution, and the contents of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and Magnolia officinalis extract in the solution are 0.001%, 0.1%, 0.001%, and 0.1% respectively.

[0070] Example 4 Preparation of Hair-Strengthening and Anti-Hair-Loss Composition 4

[0071] Mix type XVII collagen, Platycladus orientalis leaf extract, adenosine, and myristoyl pentapeptide-4 in a mass ratio of 1:100:1:1 to obtain Hair-Strengthening and Anti-Hair-Loss Composition 4.

[0072] For subsequent tests, dissolve Hair-Strengthening and Anti-Hair-Loss Composition 4 in water to prepare an aqueous solution. The contents of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and myristoyl pentapeptide-4 in the solution are 0.001%, 0.1%, 0.001%, and 0.001% respectively.

[0073] Example 5 Preparation of Hair-Strengthening and Anti-Hair-Loss Composition 5

[0074] Mix type XVII collagen, Platycladus orientalis leaf extract, adenosine, and acetyl tetrapeptide-3 in a mass ratio of 1:100:1:3 to obtain Hair-Strengthening and Anti-Hair-Loss Composition 5.

[0075] For subsequent tests, dissolve Hair-Strengthening and Anti-Hair-Loss Composition 5 in water to prepare an aqueous solution. The contents of type XVII collagen, Platycladus orientalis leaf extract, adenosine, and acetyl tetrapeptide-3 in the solution are 0.001%, 0.1%, 0.001%, and 0.003% respectively.

[0076] Comparative Example 1 Preparation of Comparative Composition 1

[0077] Mix type XVII collagen, Magnolia officinalis extract, and adenosine in a mass ratio of 1:100:1 to obtain Comparative Composition 1.

[0078] For subsequent tests, dissolve Comparative Composition 1 in water to prepare an aqueous solution. The contents of type XVII collagen, Magnolia officinalis extract, and adenosine in the solution are 0.001%, 0.1%, and 0.001% respectively.

[0079] Comparative Example 2 Preparation of Comparative Composition 2

[0080] Mix type XVII collagen, Polygonum multiflorum extract, and adenosine in a mass ratio of 1:100:1 to obtain Comparative Composition 2.

[0081] For subsequent tests, dissolve Comparative Composition 2 in water to prepare an aqueous solution. The contents of type XVII collagen, Polygonum multiflorum extract, and adenosine in the solution are 0.001%, 0.1%, and 0.001% respectively.

[0082] Comparative Example 3 Preparation of Comparative Composition 3

[0083] Mix type XVII collagen, ginger extract, and adenosine in a mass ratio of 1:100:1 to obtain Comparative Composition 3.

[0084] For subsequent tests, dissolve Comparative Composition 3 in water to prepare an aqueous solution. In the solution, the contents of type XVII collagen, ginger extract, and adenosine are 0.001%, 0.1%, and 0.001% respectively.

[0085] Comparative Example 4 Preparation of Comparative Composition 4

[0086] Mix type XVII collagen, coffee extract, and adenosine in a mass ratio of 1:2.5:1 to obtain Comparative Composition 4.

[0087] For subsequent tests, dissolve Comparative Composition 4 in water to prepare an aqueous solution. In the solution, the contents of type XVII collagen, coffee extract, and adenosine are 0.001%, 0.0025%, and 0.001% respectively.

[0088] Comparative Example 5 Preparation of Comparative Composition 5

[0089] Mix type XVII collagen, calamus extract, and adenosine in a mass ratio of 1:100:1 to obtain Comparative Composition 5.

[0090] For subsequent tests, dissolve Comparative Composition 5 in water to prepare an aqueous solution. In the solution, the contents of type XVII collagen, calamus extract, and adenosine are 0.001%, 0.1%, and 0.001% respectively.

[0091] Effect Example 1: 5α-Reductase Inhibition Rate Test

[0092] 1. Test Procedure

[0093] (1) Sample Tube: Add 1 mL of sample solution, 1 mL of enzyme solution, 1 mL of NADPH solution, and 1 mL of testosterone solution to a test tube, gently shake well, pipette 200 μL into a 96-well microplate. Do three parallels for each sample and place it in a microplate reader for detection. Measure the absorbance at 340 nm, which is the first measured value A. 样品0 Incubate the sample at 37 °C for 20 minutes, then place it in a microplate reader for detection. Measure the absorbance at 340 nm, which is the second measured value A. 样品20 .

[0094] (2) Enzyme tube: Add 1 mL of PBS solution, 1 mL of enzyme solution, 1 mL of NADPH solution, and 1 mL of testosterone solution into a test tube, gently shake well, pipette 200 μL into a 96-well microplate, make three parallels for each sample, put it into a microplate reader for detection, and measure the absorbance at 340 nm, which is the first measured value A. 酶0 After incubating the sample at 37 °C for 20 minutes, put it into a microplate reader for detection, and measure the absorbance at 340 nm, which is the second measured value A. 酶20 At the same time, perform blank and positive control detections.

[0095] (3) The 5α-reductase inhibition rate is calculated according to the following formula:

[0096]

[0097] Each sample is tested three times, and the average value is taken and recorded in Table 1.

[0098] 2. Test results

[0099]

[0100] The experimental results are shown in Table 1 and Figure 1 As shown, compared with components 1-7, Examples 1-5 have significantly improved in inhibiting 5α-reductase activity. Compared with Comparative Examples 1-5, Example 1 has a stronger ability to inhibit 5α-reductase activity. It can be seen that, compared with other plant extracts, type 17 collagen and adenosine have a better synergistic effect with Platycladus orientalis extract.

[0101] Effect Example 2: Test on the antioxidant capacity of the composition

[0102] 1. Test procedure

[0103] (1) Dermal papilla cell seeding: Seed cells into a 6-well plate at a seeding density of 3×10 5 cells / well, and place the 6-well plate in an incubator (37 °C, 5% CO 2 ) for overnight incubation.

[0104] (2) Solution preparation: Prepare test substances with different concentrations according to different test groups.

[0105] (3) H 2 O 2 stimulation: According to the test group, when the cell confluence rate in the 6-well plate reaches about 60%, perform H 2 O 2 stimulation, and the induction time is 1 hour.

[0106] (4) Administration: After the induction time ends, administer drugs according to the test group, add 2 mL of sample to each well, and set 3 replicate wells for each group. At 37 °C, 5% CO2 Incubate in an incubator for 23 hours.

[0107] (5)Reactive oxygen species (ROS) detection: After incubation, add 1 mL of DCFH-DA probe with a concentration of 10 μM to each well and incubate in an incubator (37 °C, 5% CO 2 2) for 30 minutes; discard the culture medium containing DCFH-DA, wash 3 times with PBS, digest the cells with trypsin (0.25%), wash the cells 1 time with PBS, add a certain amount of fresh PBS, and detect by flow cytometry.

[0108] (6)The ROS inhibition rate is calculated according to the following formula:

[0109]

[0110] For each sample, take the average value of the test results of 3 replicate wells and record it in Table 2.

[0111] 2. Test results

[0112]

[0113] The experimental results are shown in Table 2 and Figure 2 as follows. After treatment with components 1-7 at the above concentrations, the content of reactive oxygen species (ROS) decreased slightly. After treatment with Examples 1-5 at the above concentrations, the content of reactive oxygen species (ROS) decreased significantly. Compared with Comparative Examples 1-5, Example 1 has a stronger ability to inhibit ROS. It can be seen that, compared with other plant extracts, type XVII collagen and adenosine have a better synergistic effect with the extract of Platycladus orientalis.

[0114] Effect Example 3: Test on the ability to promote the expression of COL17, TGF-β2 and VEGFA

[0115] 1. Test procedure

[0116] (1)Seed dermal papilla cells at a density of 1.5×10 5 cells per well in a 6-well plate and incubate overnight in a CO 2 2 incubator (37 °C, 5% CO 2 2).

[0117] (2)Drug administration and stimulation. According to the test grouping, perform drug administration and stimulation simultaneously, with 3 replicate wells in each group. The BC (blank control) group adds 2 mL of culture medium to each well, the NC (negative control) group adds 2 mL of culture medium containing H 2 2 2 O to each well, the PC (positive control) group adds 2 mL of culture medium containing H 2 2 2 O and WY14643 to each well, and the sample group adds culture medium containing H2 O 2 and the culture medium of the sample to be measured at the corresponding concentration. After completion, transfer all 6-well plates to a CO 2 incubator (37 °C, 5% CO 2 ) and incubate for 24 hours.

[0118] (3)After incubation, aspirate the old liquid, wash twice with 1 mL / well of PBS, add 1 mL of AG RNAex ProReagent to each well, pipette to lyse the cells, and collect the samples. Extract RNA, reverse transcribe to cDNA, and then perform fluorescence quantitative PCR detection. Use the 2 -△△CT method for calculation.

[0119] (4)Calculation of upregulation rate:

[0120]

[0121] For each sample, take the average of the test results of 3 replicate wells and record it in Table 3 - Table 5.

[0122] 2. Test results

[0123]

[0124] The experimental results are shown in Table 3 and Figure 3 as follows. After treatment with the above concentrations, the upregulation rate of the COL 17 gene expression for Component 1 (type 17 collagen) is 44.23%, for Component 2 (extract of Platycladus orientalis leaves) is 17.31%; for Component 3 (adenosine) is 3.85%; for Component 4, after treatment with the above concentrations, the COL 17 gene expression increased slightly, but the upregulation rate did not exceed 2%; for Component 5, after treatment with the above concentrations, the upregulation rate of the COL 17 gene expression is 7.69%; for Components 6 and 7, after treatment with the above concentrations respectively, the COL 17 gene expression did not increase.

[0125] After treatment with the above concentrations respectively for Examples 1 - 5, the COL 17 gene expression increased significantly, and the upregulation rate ranged from 98.08% to 117.95%. Compared with Comparative Examples 1 - 5, Example 1 had a greater upregulation rate of the COL 17 gene expression. It can be seen that compared with other plant extracts, type 17 collagen and adenosine have a better cooperative effect with the extract of Platycladus orientalis leaves.

[0126]

[0127] As shown in Table 4 and Figure 4As shown, after treatment with the above concentrations, the upregulation rate of TGF-β2 gene expression was 144.81% for Component 1 (Collagen Type XVII), 38.31% for Component 2 (Platycladus orientalis extract), 14.94% for Component 3 (Adenosine); after treatment with the above concentrations for Components 4-7, the TGF-β2 gene expression increased slightly, but the upregulation rate did not exceed 20%.

[0128] After treatment with the above concentrations in Examples 1-5 respectively, the TGF-β2 gene expression increased significantly, and the upregulation rate ranged from 336.36% to 359.74%. Compared with Comparative Examples 1-5, Example 1 had a greater upregulation rate of TGF-β2 gene expression. It can be seen that Collagen Type XVII and Adenosine have a better cooperative effect with Platycladus orientalis extract compared to other plant extracts. The increase in TGF-β2 gene expression can promote the transformation of hair follicle stem cells from the quiescent phase to the growth phase, thus being more beneficial for hair retention.

[0129]

[0130] As shown in Table 5 and Figure 5 As shown, after treatment with the above concentrations, the upregulation rate of VEGFA gene expression was 128.16% for Component 1 (Collagen Type XVII), 63.79% for Component 2 (Platycladus orientalis extract), 12.07% for Component 3 (Adenosine); after treatment with the above concentrations for Components 4-7, the VEGFA gene expression increased slightly, but the upregulation rate did not exceed 20%.

[0131] After treatment with the above concentrations in Examples 1-5 respectively, the VEGFA gene expression increased significantly, and the upregulation rate ranged from 179.31% to 205.17%. Compared with Comparative Examples 1-5, Example 1 had a greater upregulation rate of VEGFA gene expression. It can be seen that Collagen Type XVII and Adenosine have a better cooperative effect with Platycladus orientalis extract compared to other plant extracts.

[0132] Effect Example 4: Test on the ability to reduce senescent hair follicle cells

[0133] 1. Test process

[0134] (1) Seed dermal papilla cells at a density of 1.5×10 5 cells per well in a 6-well plate and incubate overnight in a CO 2 incubator (37°C, 5% CO 2 ).

[0135] (2) Administration and stimulation. Administration and stimulation were carried out according to the test groups, with administration and stimulation being carried out simultaneously, and 3 replicate wells were set in each group. The BC (blank control) group added 2 mL of culture medium to each well, the NC (negative control) group added 2 mL of culture medium containing H 2 O 2 to each well, the PC (positive control) group added 2 mL of culture medium containing H 2 O 2 and WY14643 to each well, and the sample group added culture medium containing H 2 O 2 and the test sample at the corresponding concentration to each well. After completion, all 6-well plates were transferred to a CO 2 incubator (37 °C, 5% CO 2 ) and incubated for 24 hours.

[0136] (3) Use a β-galactosidase staining kit to stain the cells after treatment with the test substance, and count the proportion of senescent cells among all cells.

[0137] For each sample, the average value of the test results of 3 replicate wells was taken and recorded in Table 6.

[0138] 2. Test results

[0139]

[0140] The experimental results are shown in Table 6 and Figure 6 as follows. Compared with Components 1-7, Examples 1-5 showed a significant improvement in inhibiting the senescence of dermal papilla cells. Compared with Comparative Examples 1-5, Example 1 had a stronger ability to inhibit the senescence of dermal papilla cells. It can be seen that compared with other plant extracts, type 17 collagen and adenosine had a better cooperative effect with the extract of Platycladus orientalis.

[0141] Application Example 1: Preparation of hair care essence

[0142] According to the formula in Table 7, a hair care essence was prepared using the anti-hair loss and hair-fixing composition of Example 1. The preparation process was as follows:

[0143] Raw material water and dipropylene glycol were respectively added to the main pot and stirred evenly, then type 17 collagen was added and stirred until completely dissolved; the extract of Platycladus orientalis was premixed with a certain amount of water, and after premixing evenly, it was added to the main pot and stirred evenly; then adenosine, dipotassium glycyrrhizinate and VE derivative were added and stirred evenly; the pH of the material was tested, and arginine was added to adjust the pH to 6-7.

[0144]

[0145] The efficacy test of hair strengthening and hair loss prevention was carried out through mouse experiments. Mice in the telogen phase (skin is pink) were selected for the experiment. Eighteen male SPF-grade C57BL / 6 mice, 6-7 weeks old, were taken. After 7 days of adaptive feeding of the mice, they were randomly divided into 3 groups according to body weight, namely the normal control group, the positive control group, and the test article group, with 6 mice in each group. Under the anesthesia of the mice, an area of about 2 cm × 3 cm on the back was selected as the depilation area, and the long side of this area was parallel to the spine. The hair in this area was shaved off with a hair clipper and further depilated with depilatory cream. After the pre-hair treatment, the mice in the test article group were treated with the test article (hair care essence of Application Example 1) by skin application, and the intervention period was 21 days. The mice in the normal control group were smeared with physiological saline, and the positive control group was smeared with a commercially available competitor product (5% minoxidil). The specific grouping and administration information are shown in Table 8:

[0146]

[0147] Mice in each group were photographed every day before and after the intervention to record the color of the skin and hair in the depilation area. And the hair growth of the mice was scored on the 3rd, 7th, 10th, 14th, and 21st days before and after the intervention. The hair scoring criteria are shown in Table 9:

[0148]

[0149] After the administration was completed, the hair quality and hair length of the newly grown hair in the depilation area of each group of mice were detected. After the newly grown hair in the depilation area was removed, it was weighed, and the hair quality was recorded per square centimeter of skin. In addition, 50 hairs were randomly selected from each mouse, fixed with transparent tape, and the length of the newly grown hair in the depilation area was measured with a ruler, and the measurement results were recorded.

[0150] The test results showed that compared with the normal control group and the positive control group, the mice using the hair care essence of the present invention had faster hair growth. By 14 days, more than 80% of the area had hair growth, and the hair was longer and heavier.

[0151] Although the specific embodiments of the present invention have been described above, those skilled in the art should understand that this is only an example. The protection scope of the present invention is defined by the appended claims. Without departing from the principles and essence of the present invention, those skilled in the art can make various changes or modifications to these embodiments, but these changes and modifications all fall within the protection scope of the present invention.

Claims

1. A hair-fixing and anti-hair loss composition, characterized in that: The hair-fixing and anti-hair loss composition comprises type 17 collagen, plant extracts and adenosine substances, and the plant extracts comprise Platycladus orientalis leaf extracts.

2. The hair-fixing and anti-hair loss composition according to claim 1, characterized in that: The molecular weight of the type 17 collagen is 20-200 kDa, such as 23.8 kDa, 97 kDa, 120 kDa or 180 kDa.

3. The hair-fixing and anti-hair loss composition according to claim 1, characterized in that: The adenosine substance is selected from one or more of adenosine triphosphate disodium, cyclic adenosine monophosphate, adenosine phosphate, adenosine triphosphate and adenosine.

4. The hair-fixing and anti-hair loss composition according to any one of claims 1 to 3, characterized in that: The mass ratio of the type 17 collagen, the Platycladus orientalis leaf extract and the adenosine-like substance is (0.0001-0.1): (0.1-5): (0.001-0.5), for example, 1:100:

1.

5. The hair-fixing and anti-hair loss composition according to any one of claims 1 to 3, characterized in that: The hair-fixing and anti-hair loss composition further comprises a carnitine substance, wherein the carnitine substance is preferably selected from one or more of carnitine, carnitine hydrochloride, acetylcarnitine hydrochloride, carnitine tartrate and palmitoylcarnitine; Preferably, the hair solidification and anti-hair loss composition comprises type 17 collagen, Platycladus orientalis leaf extract, adenosine and carnitine tartrate; wherein the mass ratio of type 17 collagen, Platycladus orientalis leaf extract, adenosine and carnitine tartrate is preferably (0.0001-0.1): (0.1-5): (0.001-0.5): (0.003-0.5), for example, 1:100:1:

3.

6. The hair-fixing and anti-hair loss composition according to any one of claims 1 to 3, characterized in that: The plant extracts further include one or more of magnolia bark extract, polygonum multiflorum extract, ginger extract, salvia miltiorrhiza extract and coffee extract; Preferably, the hair solidification and anti-hair loss composition comprises type 17 collagen, Platycladus orientalis leaf extract, adenosine and Magnolia officinalis extract; wherein the mass ratio of type 17 collagen, Platycladus orientalis leaf extract, adenosine and Magnolia officinalis extract is preferably (0.0001-0.1): (0.1-5): (0.001-0.5): (0.1-2), for example, 1:100:1:

100.

7. The hair-fixing and anti-hair loss composition according to any one of claims 1 to 3, characterized in that: The hair-fixing and anti-hair loss composition further comprises a peptide substance, and the peptide substance is preferably selected from one or more of myristoyl pentapeptide-4, myristoyl pentapeptide-17, myristoyl tetrapeptide-12, myristoyl hexapeptide-16, acetyl tetrapeptide-3, oligopeptide-41, oligopeptide-74, copper acetate peptide, biotin tripeptide-1, acetyl octapeptide-2, tripeptide-1 copper, oligopeptide-1 and tripeptide-34 copper; Preferably, the hair-fixing and anti-hair loss composition comprises type 17 collagen, Platycladus orientalis leaf extract, adenosine and myristoyl pentapeptide-4; wherein the mass ratio of type 17 collagen, Platycladus orientalis leaf extract, adenosine and myristoyl pentapeptide-4 is preferably (0.0001-0.1): (0.1-5): (0.001-0.5): (0.001-3), for example, 1:100:1:1; Preferably, the hair solidification and anti-hair loss composition comprises type 17 collagen, Platycladus orientalis leaf extract, adenosine and acetyl tetrapeptide-3; wherein the mass ratio of type 17 collagen, Platycladus orientalis leaf extract, adenosine and acetyl tetrapeptide-3 is preferably (0.0001-0.1): (0.1-5): (0.001-0.5): (0.003-0.5), for example, 1:100:1:

3.

8. A hair-fixing and anti-hair loss product, comprising the hair-fixing and anti-hair loss composition according to any one of claims 1 to 7.

9. The hair loss prevention product according to claim 8, characterized in that: The hair-fixing and anti-hair loss product is a shampoo, a hair conditioner, a hair care essence, a shower gel or a body lotion.

10. Use of the hair-fixing and anti-hair loss composition according to any one of claims 1 to 7 in the preparation of a hair-fixing and anti-hair loss product.

Images